Other equities analysts also recently issued research reports about the company. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. Mizuho reiterated a buy rating and set a $27.00 price objective on shares of Xeris Pharmaceuticals in a research report on Thursday, July 25th.
Shares of Xeris Pharmaceuticals stock opened at $11.45 on Tuesday. Xeris Pharmaceuticals has a one year low of $6.85 and a one year high of $27.98. The company has a market cap of $315.48 million, a price-to-earnings ratio of -2.29 and a beta of -0.40. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.00 and a current ratio of 6.00. The business’s 50 day moving average price is $11.69 and its 200 day moving average price is $10.86.
A number of institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP purchased a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $118,000. Invesco Ltd. purchased a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $11,440,000. Vanguard Group Inc. raised its stake in shares of Xeris Pharmaceuticals by 7.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,219,153 shares of the company’s stock worth $13,947,000 after buying an additional 81,209 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $42,000. Finally, BlackRock Inc. raised its stake in shares of Xeris Pharmaceuticals by 19.5% during the 2nd quarter. BlackRock Inc. now owns 2,138,781 shares of the company’s stock worth $24,468,000 after buying an additional 348,308 shares in the last quarter. Hedge funds and other institutional investors own 62.29% of the company’s stock.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Further Reading: How is the Producer Price Index calculated?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.